www.fdanews.com/articles/138284-baxter-8217-s-immunodeficiency-drug-reveals-positive-results-in-phase-iii-study
Baxter’s Immunodeficiency Drug Reveals Positive Results in Phase III Study
July 11, 2011
Baxter International revealed positive results from a late-stage study of HyQ to treat primary immunodeficiency, whereby the rate of bacterial infection was much lower than the threshold level.
RTTNews
RTTNews